Paladin Labs Announces Shareholder Approval of the Plan of Arrangement

Paladin Labs Announces Shareholder Approval of the Plan of Arrangement 
NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: Paladin Labs Inc. 
TSX SYMBOL:  PLB 
FEBRUARY 24, 2014 
Paladin Labs Announces Shareholder Approval of the Plan of Arrangement 
MONTREAL, QUEBEC--(Marketwired - Feb. 24, 2014) -  
THIS MEDIA RELEASE IS NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE
SERVICES OR FOR DISSEMINATION IN THE UNITED STATES 
Paladin Labs Inc. (TSX:PLB) ("Paladin" or the
"Corporation"), a leading Canadian specialty pharmaceutical company,
is pleased to announce that an overwhelming majority of Paladin's
shareholders who voted today at Paladin's Special Meeting of Shareholders
(the "Meeting"), have voted to approve the plan of arrangement to
effect, among other things, the indirect acquisition by Endo International
Limited ("New Endo") of all outstanding shares of the Corporation
(the "Arrangement"). Over 99% of the common shares of Paladin voted
at the Meeting were voted in favor of the special resolution approving the
Arrangement.  
Completion of the transaction is subject to customary closing conditions,
including, but not limited to the approval of the transaction by the holders of
a majority of the outstanding Endo Health Solutions Inc. ("Endo")
common stock at the Endo special meeting called for this purpose to be held on
February 26, 2014 and the final approval of the Arrangement by the Superior
Court of Quebec. 
Paladin's application to the Superior Court of Quebec to obtain the final
court order approving the Arrangement is scheduled for Thursday, February 27,
2014. Assuming court approval is obtained and that all other conditions to the
Arrangement are satisfied or waived, the Arrangement is expected to become
effective on or about February 28, 2014. 
About Paladin Labs Inc.  
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products for the Canadian and world markets. With this strategy,
a focused national sales team and proven marketing expertise, Paladin has
evolved into one of Canada's leading specialty pharmaceutical companies.
Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB.
For more information about Paladin, please visit the Corporation's web
site at www.paladinlabs.com.  
About Endo Health Solutions Inc.  
Endo Health Solutions Inc. is a U.S.-based specialty healthcare company with
business segments that are focused on branded pharmaceuticals, generics, and
medical devices which deliver quality products to its customers intended to
improve the lives of patients. Through its operating companies - Endo
Pharmaceuticals, Qualitest, and AMS - Endo is dedicated to delivering value to
our stakeholders: customers, patients, and shareholders. Learn more at
www.endo.com.  
About Knight Therapeutics Inc. 
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products for the Canadian and world markets. The TSX Venture
Exchange has conditionally approved the listing of Knight Therapeutics'
shares subject only to customary conditions. For more information about Knight
Therapeutics, please visit www.sedar.com. 
This press release may contain forward-looking statements and predictions.
These forward-looking statements, by their nature, necessarily involve risks
and uncertainties that could cause actual results to differ materially from
those contemplated by the forward-looking statements. The Corporation considers
the assumptions on which these forward-looking statements are based to be
reasonable at the time they were prepared, but cautions that these assumptions
regarding the future events, many of which are beyond the control of the
Corporation and its subsidiaries, may ultimately prove to be incorrect. Factors
and risks that could cause actual results to differ materially from current
expectations include, without limitation, the failure to receive, on a timely
basis or otherwise, the required approvals by Endo Shareholders, the Superior
Court of Quebec and applicable government and regulatory authorities, the terms
of those approvals, the risk that a condition to closing contemplated by the
Arrangement Agreement may not be satisfied or waived and are otherwise as
discussed in the annual report as well as in the Corporation's Annual
Information Form for the year ended December 31, 2012. The Corporation
disclaims any intention or obligation to update or revise any forward-looking
statements whether as a result of new information or future events and except
as required by law. For additional information on risks and uncertainties
relating to these forward-looking statements, investors should consult the
Corporation's ongoing quarterly filings, annual report and Annual
Information Form and other filings found on SEDAR at www.sedar.com.  
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
CST Phoenix Advisors
Toll Free: 1-800-239-6813
inquiries@phoenixadvisorscst.com 
INDUSTRY:  Pharmaceuticals and Biotech - Biotech, Pharmaceuticals and Biotech -
Drugs, Pharmaceuticals and Biotech - Equipment and Supplies, Pharmaceuticals
and Biotech - Trials 
SUBJECT:  STK 
-0-
-0- Feb/24/2014 21:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.